In each study group , median ( range ) RSV load ( log10 copies/mL ) decreased at a similar rate from baseline to study day 7 [ motavizumab 30 mg/kg : 8.35 ( 2.5-9 .5 ) to 5.03 ( 2.5-6 .8 ) ; motavizumab 100 mg/kg : 8.22 ( 5.5-9 .7 ) to 4.25 ( 2.5-8 .0 ) ; placebo : 8.02 ( 6.7-9 .8 ) to 5.17 ( 2.5-7 .3 ) ] .